Purple Biotech (PPBT) Receivables (2019 - 2022)

Purple Biotech (PPBT) has reported Receivables for 4 consecutive years, with $431000.0 the latest figure, recorded in Q4 2022.

• On a quarterly basis, Receivables changed N/A year-over-year to $431000.0 in Q4 2022; TTM through Dec 2022 was $431000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $431000.0, changed N/A from the prior year.
• Receivables was $431000.0 for Q4 2022 at Purple Biotech, down from $500000.0 in the prior quarter.
• Over five years, Receivables peaked at $1.5 million in Q4 2019 and troughed at $431000.0 in Q4 2022.
• A 4-year average of $703428.6 and a median of $500000.0 in 2020 frame the typical range for Receivables.
• Across the five-year window, Receivables slumped 66.51% in 2020 and sank 50.0% in 2021, its largest moves.
• Over 4 years, Receivables stood at $1.5 million in 2019, then tumbled by 66.51% to $500000.0 in 2020, then changed by 0.0% to $500000.0 in 2021, then fell by 13.8% to $431000.0 in 2022.
• The last three Receivables figures came in at $431000.0 (Q4 2022), $500000.0 (Q3 2021), and $500000.0 (Q2 2021), per Business Quant data.